文献速递关节外科创伤骨科

头孢唑林在β-内酰胺过敏患者择期骨科手术中给药的安全性

Safety of Administering Cefazolin in Beta-Lactam Allergic Patients Undergoing Elective Orthopaedic Procedures.
PubMed 文献 · J Arthroplasty · 2025-05-22

该研究评估了一项质量改进方案的安全性,该方案建议对标注为β-内酰胺过敏(排除有头孢唑林过敏记录者)的择期骨科手术患者使用头孢唑林预防手术部位感染。回顾性分析521例手术,包括209例有严重β-内酰胺过敏史者,未观察到很可能相关的超敏反应,24例(5%)出现可能的术中超敏反应,其中14例因耐受后续剂量被排除与头孢唑林相关。

要点

  • 在521例标注β-内酰胺过敏的择期骨科手术患者中,无很可能相关的超敏反应。
  • 24例(5%)出现可能的术中超敏反应,其中14例因耐受后续剂量被排除与头孢唑林相关。
  • 无患者需要肾上腺素或发生严重超敏反应,也无患者被重新标注为头孢唑林过敏。

核心结论

  • 该研究显示,在标注为β-内酰胺过敏的择期骨科手术患者中,包括有严重过敏史者,使用头孢唑林预防手术部位感染是安全的。

研究设计与样本

  • 回顾性综述,纳入521例择期骨科手术,评估推荐头孢唑林用于标注β-内酰胺过敏患者(排除有头孢唑林过敏记录者)预防手术部位感染的质量改进方案实施后的超敏反应。

主要发现

  • 在521例患者中,包括209例有严重β-内酰胺过敏史者,未观察到很可能相关的超敏反应。
  • 24例患者(5%)出现可能的术中超敏反应,其中14例因耐受后续剂量被排除与头孢唑林相关。
  • 无患者需要肾上腺素或发生严重超敏反应,也无患者被重新标注为头孢唑林过敏。

临床怎么用

  • 作者认为,该研究结果支持头孢唑林作为标注β-内酰胺过敏的骨科手术患者预防手术部位感染的标准治疗,符合抗菌药物管理原则并减少对效果较差替代药物的依赖。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cefazolin is the preferred antibiotic for surgical site infection (SSI) prophylaxis in total joint arthroplasty due to its superior efficacy. However, patients labeled as allergic to beta-lactams often receive alternative antibiotics, increasing SSI risk. Despite historical concerns of cross-reactivity between penicillins and cephalosporins, recent data indicate a much lower risk, particularly for cefazolin. METHODS: This study evaluated the safety of a quality improvement protocol recommending cefazolin for SSI prophylaxis in patients labeled as beta-lactam allergic, excluding those who had documented cefazolin allergy. A retrospective review of 521 elective orthopaedic surgeries was conducted to identify hypersensitivity reactions (HSRs) following protocol implementation. Immediate HSRs were categorized as probable or possible based on perioperative clinical signs and responses to treatment. RESULTS: Among the 521 patients, including 209 who had severe beta-lactam allergy histories, no probable HSRs were observed. There were 24 patients (5%) who experienced possible intraoperative HSRs, with 14 ruled out as cefazolin-related due to tolerance of subsequent doses. No patients required epinephrine or experienced severe hypersensitivity, and none were relabeled as cefazolin-allergic. CONCLUSIONS: This study demonstrates the safety of cefazolin administration for SSI prophylaxis in beta-lactam-allergic patients, even those who had severe allergic histories. Previous studies corroborate the safety and efficacy of cefazolin compared to alternative antibiotics, supporting its use as the standard of care. The findings emphasize the safety of cefazolin for orthopaedic SSI prevention in beta-lactam-allergic patients, aligning with antimicrobial stewardship principles and reducing reliance on less effective alternatives.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Clarke ZH, Hogan CA, Dayton MR, et al. Safety of Administering Cefazolin in Beta-Lactam Allergic Patients Undergoing Elective Orthopaedic Procedures. J Arthroplasty. 2025. PMID: 40412737. doi:10.1016/j.arth.2025.05.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。